<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Brii Biosciences Ltd — News on 6ix</title>
<link>https://6ix.com/company/brii-biosciences-ltd</link>
<description>Latest news and press releases for Brii Biosciences Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sun, 26 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/brii-biosciences-ltd" rel="self" type="application/rss+xml" />
<item>
<title>Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026</title>
<link>https://6ix.com/company/brii-biosciences-ltd/news/brii-bio-presents-cross-study-analysis-of-post-treatment-hbsag-rebound-at-apasl-2026</link>
<guid isPermaLink="true">https://6ix.com/company/brii-biosciences-ltd/news/brii-bio-presents-cross-study-analysis-of-post-treatment-hbsag-rebound-at-apasl-2026</guid>
<pubDate>Sun, 26 Apr 2026 11:00:00 GMT</pubDate>
<description>Brii Biosciences Limited ("Brii Bio," "Brii," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, presented a cross-study analysis of post-treatment hepatitis B surface antigen (HBsAg) rebound profiles at the 35th Annual Meeting of Asian Pacific Association for the Study of the Liver (APASL 2026), taking place from April 22-25, 2026 in Istanbul, Turkey.</description>
</item>
<item>
<title>Brii Biosciences and OpenBench Announce AI-Driven Collaboration for Proprietary Technology Platform</title>
<link>https://6ix.com/company/brii-biosciences-ltd/news/brii-biosciences-and-openbench-announce-ai-driven-collaboration-for-proprietary-technology-platform</link>
<guid isPermaLink="true">https://6ix.com/company/brii-biosciences-ltd/news/brii-biosciences-and-openbench-announce-ai-driven-collaboration-for-proprietary-technology-platform</guid>
<pubDate>Thu, 11 Dec 2025 12:30:00 GMT</pubDate>
<description>OpenBench, Inc., a biotechnology company pioneering success-driven molecular discovery partnerships, and Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced a collaboration to leverage OpenBench's structure-based artificial intelligence platform to accelerate Brii Bio's discovery efforts and advance proprietary technology for its new discovery efforts.</description>
</item>
<item>
<title>Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B</title>
<link>https://6ix.com/company/brii-biosciences-ltd/news/brii-biosciences-presents-late-breaking-data-from-ongoing-phase-2-ensure-study-at-aasld-2025-reinforcing-brii-179s-potential-as-a-curative-treatment-for-chronic-hepatitis-b</link>
<guid isPermaLink="true">https://6ix.com/company/brii-biosciences-ltd/news/brii-biosciences-presents-late-breaking-data-from-ongoing-phase-2-ensure-study-at-aasld-2025-reinforcing-brii-179s-potential-as-a-curative-treatment-for-chronic-hepatitis-b</guid>
<pubDate>Mon, 10 Nov 2025 13:30:00 GMT</pubDate>
<description>Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced 24-week post end of treatment (EOT) follow-up results from Cohort 4 of its ongoing Phase 2 ENSURE study. These late-breaking data were presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, held in Washington D.C. from November 7-11, 2025,</description>
</item>
<item>
<title>Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine</title>
<link>https://6ix.com/company/brii-biosciences-ltd/news/brii-biosciences-announces-publication-of-phase-2-ensure-study-results-in-nature-medicine</link>
<guid isPermaLink="true">https://6ix.com/company/brii-biosciences-ltd/news/brii-biosciences-announces-publication-of-phase-2-ensure-study-results-in-nature-medicine</guid>
<pubDate>Fri, 07 Nov 2025 13:30:00 GMT</pubDate>
<description>Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical need, today announced the publication of results from its Phase 2 ENSURE study in the peer-reviewed journal Nature Medicine. The study evaluates the efficacy and safety of an siRNA, elebsiran, in combination with pegylated interferon alfa (PEG-IFNα), compared to PEG-IFNα monotherapy. Furthermore, this study ev</description>
</item>
<item>
<title>Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results</title>
<link>https://6ix.com/company/brii-biosciences-ltd/news/brii-biosciences-provides-corporate-updates-and-reports-2025-interim-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/brii-biosciences-ltd/news/brii-biosciences-provides-corporate-updates-and-reports-2025-interim-financial-results</guid>
<pubDate>Thu, 21 Aug 2025 10:02:00 GMT</pubDate>
<description>Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical need, today provided a corporate update and reported its financial results for the six-month period ended June 30, 2025.</description>
</item>
<item>
<title>Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China</title>
<link>https://6ix.com/company/brii-biosciences-ltd/news/brii-biosciences-announces-licensing-agreement-with-joincare-group-for-rights-to-brii-693-in-greater-china</link>
<guid isPermaLink="true">https://6ix.com/company/brii-biosciences-ltd/news/brii-biosciences-announces-licensing-agreement-with-joincare-group-for-rights-to-brii-693-in-greater-china</guid>
<pubDate>Fri, 04 Jul 2025 00:30:00 GMT</pubDate>
<description>Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced that it has entered into a license and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd ("Joincare Group"). Joincare Group will obtain an exclusive license from Brii Bio for the research, development, and commercialization of BRII-693 in the Greater China regio</description>
</item>
<item>
<title>Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss</title>
<link>https://6ix.com/company/brii-biosciences-ltd/news/brii-bio-presents-late-breaking-data-from-its-ongoing-phase-2-ensure-study-at-easl-congress-2025-suggesting-brii-179s-role-in-advancing-higher-hbsag-loss</link>
<guid isPermaLink="true">https://6ix.com/company/brii-biosciences-ltd/news/brii-bio-presents-late-breaking-data-from-its-ongoing-phase-2-ensure-study-at-easl-congress-2025-suggesting-brii-179s-role-in-advancing-higher-hbsag-loss</guid>
<pubDate>Thu, 08 May 2025 00:10:00 GMT</pubDate>
<description>Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced data from its ongoing Phase 2 ENSURE study as late-breaking posters at the European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam, the Netherlands.</description>
</item>
<item>
<title>Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification</title>
<link>https://6ix.com/company/brii-biosciences-ltd/news/brii-bio-unveils-new-data-from-its-ongoing-phase-2-ensure-study-at-apasl-2025-showcasing-brii-179s-unique-potential-to-prime-and-boost-higher-hbsag-loss-through-target-patient-identification</link>
<guid isPermaLink="true">https://6ix.com/company/brii-biosciences-ltd/news/brii-bio-unveils-new-data-from-its-ongoing-phase-2-ensure-study-at-apasl-2025-showcasing-brii-179s-unique-potential-to-prime-and-boost-higher-hbsag-loss-through-target-patient-identification</guid>
<pubDate>Sun, 30 Mar 2025 11:10:00 GMT</pubDate>
<description>Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the 34th Annual Meeting of Asian Pacific Association for the Study of the Liver (APASL 2025) in Beijing, China.</description>
</item>
<item>
<title>Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results</title>
<link>https://6ix.com/company/brii-biosciences-ltd/news/brii-biosciences-provides-corporate-update-and-reports-full-year-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/brii-biosciences-ltd/news/brii-biosciences-provides-corporate-update-and-reports-full-year-2024-financial-results</guid>
<pubDate>Fri, 21 Mar 2025 11:10:00 GMT</pubDate>
<description>Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical needs provided a corporate update today and reported its financial results for the year ended December 31, 2024.</description>
</item>
</channel>
</rss>